EMMA Stock Overview
A commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.028 |
| 52 Week High | US$0.14 |
| 52 Week Low | US$0.0001 |
| Beta | 6.6 |
| 11 Month Change | 12.40% |
| 3 Month Change | 28,000.00% |
| 1 Year Change | -76.58% |
| 33 Year Change | -98.13% |
| 5 Year Change | -98.80% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMMA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -23.0% | -1.4% | 0.3% |
| 1Y | -76.6% | 10.8% | 31.1% |
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: EMMA underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| EMMA volatility | |
|---|---|
| EMMA Average Weekly Movement | 490.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMMA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EMMA's weekly volatility has increased from 258% to 490% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 53 | Willis Lee | www.emmausmedical.com |
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study.
Emmaus Life Sciences, Inc. Fundamentals Summary
| EMMA fundamental statistics | |
|---|---|
| Market cap | US$1.79m |
| Earnings (TTM) | -US$3.50m |
| Revenue (TTM) | US$20.43m |
0.1x
P/S Ratio-0.5x
P/E RatioIs EMMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMMA income statement (TTM) | |
|---|---|
| Revenue | US$20.43m |
| Cost of Revenue | US$1.08m |
| Gross Profit | US$19.35m |
| Other Expenses | US$22.84m |
| Earnings | -US$3.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | 94.70% |
| Net Profit Margin | -17.11% |
| Debt/Equity Ratio | -54.2% |
How did EMMA perform over the long term?
See historical performance and comparison